Europe PMC
open access
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer#1161572
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients#1096398
- Raman analysis of breast cancer-associated adipocytes: A chemometric pipeline for lipid biochemistry profiling.#236092
- AXL-driven stemness and hedgehog signaling in HER2-positive breast cancer with acquired trastuzumab resistance: synergistic potential of AXL and HER2 co-targeting#194877
- From phytochemical characterization to energy metabolism-driven molecular responses: the anticancer potential of lactarius deliciosus (l.) gray in breast cancer cells#194871
Record · ID 202219
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive